FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012514660> ?p ?o ?g. }

• W2012514660 endingPage "498" @default.
• W2012514660 startingPage "496" @default.
• W2012514660 abstract "L’aripiprazole est un antipsychotique atypique avec un profil pharmacologique différent des autres antipsychotiques de seconde génération. Il présente une forte affinité pour les récepteurs dopaminergiques D2 et D3 et sérotoninergiques 5HT1A et 5HT2 ainsi qu’une bonne tolérance extrapyramidale. Nous rapportons ici le cas d’une patiente présentant une schizophrénie paranoïde ayant développé un syndrome parkinsonien après un mois de traitement par aripiprazole à 10 mg/j sans prescription associée hormis du diazépam à faible posologie. Le syndrome parkinsonien s’est complètement amendé en quelques jours après diminution de la posologie d’aripiprazole à 5 mg/j. Peu de cas de syndromes parkinsoniens sous aripiprazole ont été décrits dans la littérature, notamment chez l’adulte et sans prescrition associée d’antidépresseurs inhibiteurs spécifiques de la recapture de la sérotonine ou inhibiteurs de la recapture de la sérotonine et de la noradrénaline. L’hypothèse étiologique proposée ici serait l’implication majeure du cytochrome P450 2D6 dans le métabolisme de l’aripiprazole et de la rispéridone et la possibilité que la patiente soit un métaboliseur lent du cytochrome P450 2D6, ce qui expliquerait la régression complète du syndrome parkinsonien après réduction de la posologie d’aripiprazole. Aripiprazole is an atypical antipsychotic with a pharmacological profile, different from other atypical antipsychotics. It is a high-affinity partial agonist at the dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2 receptors. It is associated with a good safety and tolerability profile including extrapyramidal side-effects. We report on a 37 year-old female patient with paranoid schizophrenia who developed Parkinsonian symptoms after one month of aripiprazole 10 mg per day. She had been admitted to our unit for a psychotic episode with delusions of persecution and grandiosity. It was her second hospitalization. During the first hospitalization, seven years earlier, she had been treated with haloperidol. We do not have any information about the tolerability of that treatment. At the start, she received olanzapine with good tolerability but without efficacy on psychotic symptoms. After 4 weeks, we switched from olanzapine to risperidone 6 mg per day. After a few days, the patient developed severe Parkinsonian symptoms. We reduced the dose to 4 mg per day without any effect on the extrapyramidal symptoms.We decided to discontinue risperidone and to introduce aripiprazole 10 mg per day. After one month, the patient developed severe Parkinsonian symptoms including hypertonia, akinesia, and shuffling gait. After reduction of the dose of Aripiprazole to 5 mg per day, all the Parkinsonian symptoms had disappeared within 5 days without any other medication. Few reports of Parkinsonian symptoms with aripiprazole have been published in the adult population. There is one report of Parkinsonian symptoms, associated with hypersalivation without akathisia, in a patient treated with 30 mg per day of aripiprazole. All the symptoms disappeared after a switch to olanzapine. The other cases have been reported when aripiprazole was associated with anti-depressant serotonin specific reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. One report has been published of a 16 year-old girl who had already developed extrapyramidal symptoms with olanzapine and risperidone. Another has been published concerning a 3 year-old child who had taken a half tablet of aripiprazole 15 mg. We hypothesise that cytochrome P450 2D6 is implicated in this case-report because it is active in metabolizing aripiprazole. This patient could have been deficient in this enzyme, thus failing to metabolize aripiprazole at a normal rate." @default.
• W2012514660 created "2016-06-24" @default.
• W2012514660 creator A5001234972 @default.
• W2012514660 creator A5004620446 @default.
• W2012514660 creator A5054754338 @default.
• W2012514660 date "2009-10-01" @default.
• W2012514660 modified "2023-09-25" @default.
• W2012514660 title "Syndrome parkinsonien sous aripiprazole : à propos d’un cas" @default.
• W2012514660 cites W1964688493 @default.
• W2012514660 cites W1965727964 @default.
• W2012514660 cites W1971179661 @default.
• W2012514660 cites W2002841728 @default.
• W2012514660 cites W2009532179 @default.
• W2012514660 cites W2010741426 @default.
• W2012514660 cites W2013224655 @default.
• W2012514660 cites W2023196627 @default.
• W2012514660 cites W2066263996 @default.
• W2012514660 cites W2067345113 @default.
• W2012514660 cites W2069407352 @default.
• W2012514660 cites W2070895158 @default.
• W2012514660 cites W2095106622 @default.
• W2012514660 cites W2135451582 @default.
• W2012514660 doi "https://doi.org/10.1016/j.encep.2008.06.019" @default.
• W2012514660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19853725" @default.
• W2012514660 hasPublicationYear "2009" @default.
• W2012514660 type Work @default.
• W2012514660 sameAs 2012514660 @default.
• W2012514660 citedByCount "3" @default.
• W2012514660 countsByYear W20125146602022 @default.
• W2012514660 crossrefType "journal-article" @default.
• W2012514660 hasAuthorship W2012514660A5001234972 @default.
• W2012514660 hasAuthorship W2012514660A5004620446 @default.
• W2012514660 hasAuthorship W2012514660A5054754338 @default.
• W2012514660 hasConcept C118552586 @default.
• W2012514660 hasConcept C126322002 @default.
• W2012514660 hasConcept C138885662 @default.
• W2012514660 hasConcept C15744967 @default.
• W2012514660 hasConcept C170493617 @default.
• W2012514660 hasConcept C2776412080 @default.
• W2012514660 hasConcept C2778938600 @default.
• W2012514660 hasConcept C2780211496 @default.
• W2012514660 hasConcept C29456083 @default.
• W2012514660 hasConcept C58732023 @default.
• W2012514660 hasConcept C71924100 @default.
• W2012514660 hasConceptScore W2012514660C118552586 @default.
• W2012514660 hasConceptScore W2012514660C126322002 @default.
• W2012514660 hasConceptScore W2012514660C138885662 @default.
• W2012514660 hasConceptScore W2012514660C15744967 @default.
• W2012514660 hasConceptScore W2012514660C170493617 @default.
• W2012514660 hasConceptScore W2012514660C2776412080 @default.
• W2012514660 hasConceptScore W2012514660C2778938600 @default.
• W2012514660 hasConceptScore W2012514660C2780211496 @default.
• W2012514660 hasConceptScore W2012514660C29456083 @default.
• W2012514660 hasConceptScore W2012514660C58732023 @default.
• W2012514660 hasConceptScore W2012514660C71924100 @default.
• W2012514660 hasIssue "5" @default.
• W2012514660 hasLocation W20125146601 @default.
• W2012514660 hasLocation W20125146602 @default.
• W2012514660 hasOpenAccess W2012514660 @default.
• W2012514660 hasPrimaryLocation W20125146601 @default.
• W2012514660 hasRelatedWork W2008122290 @default.
• W2012514660 hasRelatedWork W2009790890 @default.
• W2012514660 hasRelatedWork W2017348745 @default.
• W2012514660 hasRelatedWork W2033660427 @default.
• W2012514660 hasRelatedWork W2034629571 @default.
• W2012514660 hasRelatedWork W2150227006 @default.
• W2012514660 hasRelatedWork W2345647650 @default.
• W2012514660 hasRelatedWork W2392794121 @default.
• W2012514660 hasRelatedWork W2748952813 @default.
• W2012514660 hasRelatedWork W2899084033 @default.
• W2012514660 hasVolume "35" @default.
• W2012514660 isParatext "false" @default.
• W2012514660 isRetracted "false" @default.
• W2012514660 magId "2012514660" @default.
• W2012514660 workType "article" @default.